Published in Brain Pathol on September 01, 2014
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet (2005) 5.81
Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature (2002) 5.21
Preservation of hearing in cochlear implant surgery: advantages of combined electrical and acoustical speech processing. Laryngoscope (2005) 3.36
Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science (2003) 3.21
Titin mutation segregates with hereditary myopathy with early respiratory failure. Brain (2012) 3.02
Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain (2005) 2.67
Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci (2008) 2.51
Combining acoustic and electrical speech processing: Iowa/Nucleus hybrid implant. Acta Otolaryngol (2004) 2.44
Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell (2004) 2.33
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain (2004) 2.20
Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain (2010) 2.19
Posttranslational modification of alpha-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. J Virol (2005) 2.17
Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain (2011) 2.13
Acoustic plus electric speech processing: preliminary results of a multicenter clinical trial of the Iowa/Nucleus Hybrid implant. Audiol Neurootol (2006) 2.10
Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. Arch Neurol (2005) 2.06
Abnormal coronary function in mice deficient in alpha1H T-type Ca2+ channels. Science (2003) 2.05
Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell (2002) 2.01
Accuracy of cochlear implant recipients on pitch perception, melody recognition, and speech reception in noise. Ear Hear (2007) 2.01
A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain (2011) 1.89
Music perception with cochlear implants and residual hearing. Audiol Neurootol (2006) 1.88
Recognition of familiar melodies by adult cochlear implant recipients and normal-hearing adults. Cochlear Implants Int (2002) 1.87
Unique role of dystroglycan in peripheral nerve myelination, nodal structure, and sodium channel stabilization. Neuron (2003) 1.80
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol (2013) 1.75
Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord (2012) 1.75
Neuropathological findings in benign tremulous parkinsonism. Mov Disord (2012) 1.74
Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathol (2011) 1.71
Parkin disease: a clinicopathologic entity? JAMA Neurol (2013) 1.68
Titin founder mutation is a common cause of myofibrillar myopathy with early respiratory failure. J Neurol Neurosurg Psychiatry (2013) 1.64
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63
Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet (2010) 1.62
Neurofilament inclusion body disease: a new proteinopathy? Brain (2003) 1.59
Limb-girdle muscular dystrophy in the United States. J Neuropathol Exp Neurol (2006) 1.59
Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol (2009) 1.57
Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol (2011) 1.57
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging (2010) 1.56
Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol (2003) 1.56
Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain (2007) 1.52
Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord (2007) 1.52
Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet (2005) 1.51
Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1. J Neurol Neurosurg Psychiatry (2013) 1.50
Using a cross-coil to reduce RF heating by an order of magnitude in triple-resonance multinuclear MAS at high fields. J Magn Reson (2006) 1.46
Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. Hum Mol Genet (2009) 1.37
Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain (2010) 1.34
From T-tubule to sarcolemma: damage-induced dysferlin translocation in early myogenesis. FASEB J (2007) 1.34
Sporadic and familial cerebral amyloid angiopathies. Brain Pathol (2002) 1.33
Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol (2005) 1.32
Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol (2005) 1.30
International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum (2007) 1.28
New aspects on patients affected by dysferlin deficient muscular dystrophy. J Neurol Neurosurg Psychiatry (2009) 1.28
Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality. Circulation (2003) 1.27
Loss of sarcolemma nNOS in sarcoglycan-deficient muscle. FASEB J (2002) 1.26
Conspicuous involvement of desmin tail mutations in diverse cardiac and skeletal myopathies. Hum Mutat (2007) 1.24
Brain and eye malformations resembling Walker-Warburg syndrome are recapitulated in mice by dystroglycan deletion in the epiblast. J Neurosci (2008) 1.22
Dysferlin associates with the developing T-tubule system in rodent and human skeletal muscle. Muscle Nerve (2010) 1.21
Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol (2008) 1.15
Strawberries on the brain--intracranial capillary hemangioma: two case reports and systematic literature review in children and adults. World Neurosurg (2012) 1.14
MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol (2004) 1.13
Disruption of perlecan binding and matrix assembly by post-translational or genetic disruption of dystroglycan function. FEBS Lett (2005) 1.12
Genetic dysfunction of MT-ATP6 causes axonal Charcot-Marie-Tooth disease. Neurology (2012) 1.11
A clinical, genetic and biochemical study of SPG7 mutations in hereditary spastic paraplegia. Brain (2004) 1.11
The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. Neurobiol Aging (2012) 1.07
Cardiomyocyte apoptosis triggered by RAFTK/pyk2 via Src kinase is antagonized by paxillin. J Biol Chem (2004) 1.06
UCHL-1 is not a Parkinson's disease susceptibility gene. Ann Neurol (2006) 1.06
Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci Transl Med (2012) 1.06
A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open (2014) 1.04
Comparison of the glidescope, CMAC, storz DCI with the Macintosh laryngoscope during simulated difficult laryngoscopy: a manikin study. BMC Anesthesiol (2012) 1.03
Brain biopsy in dementia: clinical indications and diagnostic approach. Acta Neuropathol (2010) 1.03
The relationship between addiction and reward bundling: an experiment comparing smokers and non-smokers. Addiction (2010) 1.01
The phenomenon of disproportionate antecollis in Parkinson's disease and multiple system atrophy. Mov Disord (2007) 1.01
Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. J Neurooncol (2008) 1.00
Is it really myositis? A consideration of the differential diagnosis. Curr Opin Rheumatol (2004) 1.00
Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia (2014) 0.99
Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain (2007) 0.98
Sarcoglycanopathies: can muscle immunoanalysis predict the genotype? Neuromuscul Disord (2008) 0.98
Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations. Stem Cells Dev (2013) 0.95
ANO5 gene analysis in a large cohort of patients with anoctaminopathy: confirmation of male prevalence and high occurrence of the common exon 5 gene mutation. Hum Mutat (2013) 0.95
Dopamine reverses reward insensitivity in apathy following globus pallidus lesions. Cortex (2012) 0.95
Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J Neuropathol Exp Neurol (2009) 0.95
Identification and quantification of oligodendrocyte precursor cells in multiple system atrophy, progressive supranuclear palsy and Parkinson's disease. Brain Pathol (2012) 0.93
Regional differences in the severity of Lewy body pathology across the olfactory cortex. Neurosci Lett (2009) 0.93
Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease. J Parkinsons Dis (2011) 0.93
Difference in MSA phenotype distribution between populations: genetics or environment? J Parkinsons Dis (2012) 0.92
Kearns-Sayre syndrome caused by defective R1/p53R2 assembly. J Med Genet (2011) 0.92
Recessive desmin-null muscular dystrophy with central nuclei and mitochondrial abnormalities. Acta Neuropathol (2013) 0.91
Gene transfer establishes primacy of striated vs. smooth muscle sarcoglycan complex in limb-girdle muscular dystrophy. Proc Natl Acad Sci U S A (2003) 0.91
Transportin1: a marker of FTLD-FUS. Acta Neuropathol (2011) 0.89
Caveolinopathy--new mutations and additional symptoms. Neuromuscul Disord (2008) 0.88
Immunohistochemical analysis of calpain 3: advantages and limitations in diagnosing LGMD2A. Neuromuscul Disord (2009) 0.88
Cell stiffness and receptors: evidence for cytoskeletal subnetworks. Am J Physiol Cell Physiol (2004) 0.88
The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia. Neurodegener Dis (2013) 0.88